Company intelligence / Profile preview

ProMab Biotechnologies

Richmond / San Pablo, California, United Statespromab.com ↗

Ownership: Private
Employees: ~25
Development stage: Phase 2

Overview

ProMab has generated over 5,000 monoclonal antibodies and completed more than 500 CAR-T projects. The company’s technologies have advanced into at least four Phase 2 clinical trials via partnerships or clients but does not itself sponsor late-stage commercial programs directly as it operates primarily as a service provider/CRO/CDMO. Its proprietary platforms are validated in both preclinical models and early-phase human studies.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)Recombinant proteinsEngineered cell linesCAR-T cellsCAR-NK cellsmRNA-Lipid Nanoparticles (mRNA-LNPs)Bispecific antibodies
Industry: Contract Research Organization

Partnerships

NantKwest/NantCell (now ImmunityBio): Licensing agreement for next-generation NK cell therapeutics using ProMab’s technologyOther partnerships with biotechnology startups and pharmaceutical companies for outlicensing of antibody/CAR technologies

Beyond the preview

Go deeper on ProMab Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProMab Biotechnologies.

Explore the full profile